Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (Nexavar), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma

Trial Profile

Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (Nexavar), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs THR 317 (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 May 2012 Actual patient number 6 added as reported by ClinicalTrials.gov.
    • 21 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top